J&J's daily add-on pill improves depression and insomnia symptoms, acing phase 3
29 May 2024
Clinical ResultPhase 3ASCO
Preview
Source: FierceBiotech
Currently, no approved therapies exist for treating major depressive disorder with insomnia symptoms.
Johnson & Johnson’s oral add-on drug significantly improved depressive symptoms and sleep outcomes in a phase 3 trial for patients who previously did not benefit from antidepressants alone.
The top-line results are from a pivotal clinical trial that enrolled 588 adult and elderly patients with major depressive disorder (MDD) and insomnia symptoms. J&J is sharing the findings at this year’s ongoing American Society of Clinical Psychopharmacology Annual Meeting in Florida.
The late-stage study evaluated seltorexant, a selective antagonist of the human orexin-2 receptor, as a daily adjunctive to background SSRI/SNRI antidepressants.
Seltorexant demonstrated a statistically significant improvement in depressive symptoms at day 43 compared to placebo. The investigational drug was also tied to improved sleep disturbance outcomes and was found to be safe and well-tolerated.
The trial achieved all 15 primary and 10 secondary endpoints, according to J&J.
“Depression is a leading cause of disability worldwide and shares a strong link with sleep disturbances,” Andrew Krystal, M.D., psychiatry professor at the University of California, San Francisco Weill Institute for Neurosciences, said in a May 29 release. “In MDD, insomnia symptoms exacerbate the risk of depressive relapse, increase healthcare costs and impact quality of life, and it often goes under-treated despite being one of the most common residual symptoms.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.